MBBS
MD
DM (Neurology), PhD

June 1982-May1985	:	Completed postgraduate training in Internal Medicine during which period taught Clinical Medicine to undergraduates.
January 1986-December 1988	:	Completed Post-Doctoral Fellowship (DM) in Neurology during which period actively participated in teaching undergraduates, postgraduates in Medicine, Psychiatry and Paediatrics.
April 1990-January 1995	:	Worked as Assistant Professor in Neurology. During this period has organized and actively participated in teaching undergraduate and post-graduates in Medicine, Paediatrics and Psychiatry. Actively involved in the training programme for DM post-graduates and was in charge of organizing and implementing the teaching programs. Also conducted bedside teaching, delivered lectures and moderated seminars, journal clubs and other academic activities. Responsibilities included the task of setting entrance examination question papers for selection of DM postgraduates.
January 1995 -1998	:	Working as Associate Professor in Neurology,Kasturba Medical College, Manipal and Mangalore, India. Was responsible for setting up the neurology intensive care unit at University Medical centre( the superspeciality hospital of Kasturba Medical College, Mangalore). In addition to routine academic work, was also a guide for MD Medicine postgraduates.
June 2000 –December 2015	:	Working as Professor of Medicine (Neurology), involved in teaching final year medical undergraduates and post graduates in Medicine, Pediatrics & Psychiatry.
April 2007- Present	:	Director, Center for Advanced neurological research. This center which was set up with modest philanthropic donations in 2007, is the first and only clinician driven basic science center at Nitte (Deemed to be University). It grew in stature from a modest PCR laboratory to a research facility with capability for real time PCR work, cell culture and bioassay and Flowcytometry. It is a recognized center for the awarding of PhD in Biosciences.
January 2016 onwards	:	Professor and Head, Department of Neurology, KS Hegde Medical Academy, Nitte (Deemed to be University).
August 2018 - January 2019	:	Visiting Professor, Department of Neurology, Harvard medical School (Brigham and Women's Hospital)
February 2019 onward	:	Professor of Neurology & Director of Center for Advanced Neurological Research

Research Training and Experience

1. Research Fellowship in the United Kingdom- (1995-1997). Worked as Research Fellow in Clinical Neurology (Demyelinating disorders) at Royal Victoria Infirmary, Newcastle and Research Associate at the University of Newcastle, United Kingdom. Worked on the following projects (see publications)
   1. Evaluation of the effect of I.V. Methyl prednisolone on the Cytokine Profile (tumour necrosis factor – alpha) and soluble adhesion molecules (VCAM I and ICAM I) in Multiple Sclerosis.
   2. Assessment of disability in Multiple sclerosis-a clinical and radiological study.
   3. Research associate and local (Newcastle) treating physician for the following trials
   1. Double-blind randomised multicentre European trails on Beta-Interferon Ia (Serono REBIF), Beta Interferon Ib (Schering)
   2. Double-blind randomised multicentre European trails on Beta Interferon Ia (Avonex) studies in Multiple sclerosis
   3. Phase II Double blind placebo controlled study of clinical effects of Lexipafant (British Biotech) in patients with multiple sclerosis.
2. Research Associate –Department of Molecular and Fisheries Microbiology, College of Fisheries, University of Agricultural Sciences, Mangalore, Karnataka. (2000- 2003). Worked on the following projects (See publications)
   1. Evaluation of the use of universal primers – (16s rRNA) in the diagnosis of Culture negative meningitis.
   2. Use of seminested PCR strategy in the diagnosis of culture negative meningitis
   3. Diagnostic utility of Methylation PCR in the evaluation of fragile X Mental retardation.
   4. Molecular diagnosis of Campylobacter jejuni infection in Guillain Barre Syndrome.
3. Research training in Multiple sclerosis Genetics – University of Cambridge (December 2009-2010 April). Worked as the Jaquelline Du Pre awardee of 2009-2010 in The Department of Neurology, Addenbrookes Hospital, Cambridge, UK.

My academic interests are focused on central nervous system demyelinating disorders and in particular Multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD). Since 2007 I have established a registry for demyelinating CNS disorders at my university, in the southwest part of India at Mangalore. This registry has patients from around 300 sq. kilometer radius and beyond and is one of the few dedicated to the study and care of patients suffering from demyelinating disorders in India. In the past decade, we have studied the clinical and demographic features of these disorders, conducted longitudinal follow-up studies, and published the first population-based prevalence study in our country. Simultaneously we have, based on our experiences, established cost-effective treatment algorithms for the management of patients in resource-poor settings which have now become standard of care in our part of the world. I have additionally special interest in the characterization of optic neuritis, particularly in the detection of clinically silent disease using optical coherence tomography and specialized electro retinography.

Alongside clinical work, I have researched and published my work on the genetic susceptibility for MS and NMOSD in the south Indian population. Our studies support the notion that ethnicity may not be a significant contributing factor that influences genetic susceptibility for these diseases. My lab is currently funded for developing novel diagnostic biomarkers and animal models for studying NMOSD. My responsibilities have additionally included teaching of medical undergraduates, post graduates in Internal medicine, Psychiatry, and Pediatrics and providing guidance for Ph.D. students in my lab.

1. Visiting Professor, Department of Neurology, Harvard medical School (Brigham and Women's Hospital) - August 2018- January 2019.
2. Fulbright-Nehru Scholar (Academic & Professional Excellence)-2018.
3. Nominated as member/ Chairperson of the Institutional ethics committee of Sree Chitra Tirunal Institute for Medical Sciences & Technology - 2017- 2018.
4. Nominated Member, Central Organizing Committee of  Pan Asian committee for treatment and research in Multiple sclerosis ( PACTRIMS) - 2015 - present 
5. Nominated member of International Medical Consortium- Guthy Jackson Neuromyelitis optica (NMO) foundation, USA-2013- present 
6. Member of the advisory group, World atlas of Multiple sclerosis, 2nd edition, Multiple Sclerosis International federation (MSIF) - 2012 -2013.
7. National Convenor, Indian Academy of Neurology- subsection on Autoimmune CNS disorders - 2013- 2017.
8. India representative at Multiple sclerosis International federation (MSIF) -2009-2011.
9. India representative at Asia Pacific Expert committee on Multiple sclerosis (APEC) - 2011-2013
10. Best researcher and Investigator award for work on "Genetic susceptibility for Multiple sclerosis in Indian population" by Pan Asian Committee for treatment and Research in Multiple sclerosis [PACTRIMS] -2010.
11. Jaquelline du Pre Grant from Multiple sclerosis International federation, United Kingdom - 2010-2011.
12. Rhodes Scholar Mridula Shastri memorial fellowship -1995.
    

Undergraduate and post graduate teaching and guideship for PhD students

List of Membership in Academic Bodies

• Permanent member, Neurological Society of India
• Permanent member, Indian Academy of Neurology
• Life Member, Multiple Sclerosis Society of India
• Member, National Medical Panel for Multiple sclerosis
• Member, International medical and scientific board of Multiple sclerosis International Federation (MSIF)
• Life member, Indian Society of Human Genetics

List of Professional reviews

• Multiple Sclerosis and related disorders
• Multiple sclerosis Journal
• Multiple Sclerosis Clinical Experimental &Translational
• Journal of Neurological sciences
• BMC Neurology
• Journal of Neurology, Neurosurgery, Psychiatry
• Frontiers Neurology
• Editorial board member of Neuroimmunology journal

List of National reviews

• Neurology India
• Annals of Indian Academy of Neurology
• Indian Journal of medical research

Neurology

1. Dr Lekha Pandit was invited as speaker on A WEBINAR ON MULTIPLE SCLEROSIS-PANEL DISCUSSION. A public awareness and education programme and advice by experts on different aspects of multiple sclerosis conducted by Indian Academy of Neurology on WORLD BRAIN DAY on 22-07-2021.
2. An online interview was conducted with Dr Lekha Pandit, on promotion of World Brain day by World Federation of Neurology (WFN), addressing management of Multiple Sclerosis in resource poor settings on 10-06-2021.
3. Dr Lekha Pandit, was invited as speaker at" Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS) inaugural educational webinar PACTMAN series 01 " held Virtual on 29-04-2021.
4. Dr Lekha Pandit was invited to speak at the 8th European committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Focused Workshop 2021 on "The Risk of Infections for MS Disease Modifying Treatments (DMTs)" which was held fully digital on 14 and 21 April 2021.
5. The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) has initiated a collaborative effort to update recommendations for clinical approaches to the differential diagnosis of MS.On behalf of the steering committee of the international MS Differential Diagnosis Consortium, Dr Lekha Pandit is invited to participate in the working group to produce a paper for the topic titled " Differential Diagnosis Considerations in Non-Western Geographic Regions".
6. Dr Lekha Pandit delivered an online lecture titled "Autologous hematopoietic stem cell transplant (aHSCT) as standard of care in multiple sclerosis- Not enough evidence for such recommendation" in VIRTUAL AGRIM NEUROLOGY UPDATE (VANU) 2020 on 16th October 2020.
7. Invited online lecture by Dr Lekha Pandit on "Bio-markers interpretation in Demyelinating Disease and Overview of Sero-Negative NMOSD" conducted by Bangur Institute of Neurosciences Demyelination Clinic PDT CME on 1st October 2020.
8. Dr Lekha Pandit delivered a lecture on the topic titled "Management of Multiple Sclerosis" conducted by Bangur Institute of Neurosciences Demyelination Clinic PDT CME on 8th October 2020.
9. Dr Lekha Pandit spoke on management of multiple sclerosis and related disorders during the Covid Pandemic -National Webinar organised Intas Biopharmaceuticals on 28th April 2020.
10. Pandit L was invited to speak on ""Risk of Infections in MS DMTs", at the 8th ECTRIMS on 12-13 March 2020 in Tel Aviv, Israel.
11. Task Force meeting on "National Multiple Sclerosis and Allied Demyelinating Disorders Registry and Research Network of India. Pandit L -Running a registry and optimising data collection at National institute of medical statistics, ICMR, New Delhi. 23.10.2019.
12. Pandit L - Treatment challenges in MOG-IgG disease, in the plenary session of the first congress of Sri Lanka committee for  Treatment and Research in Multiple sclerosis and related disorders, at Colombo on
13. Pandit L -Gut Microbiome in Autoimmune CNS disorders among Indian population - at the Annual conference of the Indian Academy of Neurology, at Hyderabad, India on 4th October, 2019.
14. Pandit L presented a poster at the 35th congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the 24th Annual conference of Rehabilitation in MS (RIMS), titled " Lachnoclostridium species are elevated in Aquaporin-4 IgG+ Neuromyelitis Optica Spectrum Disorders in India and exhibit sequence similarity with AQP4" (11-13 September 2019 Stockholm, Sweden) .
15. Pandit L was invited as the Multiple Sclerosis expert from Asia Pacific region for the meeting of the International Working Group on Access to treatment (IWGA) for Multiple Sclerosis (11-12th July 2019, London)
16. Pandit L was an invited principal speaker and chairperson for Neuro Immunology session at 1st East Zone Neuro PDT CME 2019 (May 2019, Kolkata).
17. Pandit L. Demyelinating CNS Disorders in women with emphasis on MS and NMO. Invited speaker at Women In Neurology- New & Emerging Research Symposium (March 2018, Udaipur).
18. Pandit L was invited to attend and present in the Guthy -Jackson Charitable foundation 's Annual NMO Roundtable Conference March 2018
19. Pandit L. Autoimmune Encephalitis. Invited speaker at the 10th Congress of the Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS) in November 2017 at Ho Chi Minh City, Vietnam.
20. Pandit L was invited to attend and present in the Guthy -Jackson Charitable foundation 's Annual NMO Roundtable Conference 2017 from, March 12th to14th 2017
21. Pandit L. Differentiating Multiple Sclerosis from NMOSD in the clinic. Invited speaker at IANCON, Kolkata November 2016
22. Pandit L. Characterization of seronegative neuromyelitis optica in 2016. Paper presented at ECTRIMS, United Kingdom September 2016,
23. Pandit L. Different approaches in diverse clinical settings in Multiple sclerosis management - 'Ideal' vs practical realities of 'Real world'. Talk delivered at MS Expert meeting (Biogen), Athens, Greece, May 2016.
24. Pandit L was invited to attend the Guthy -Jackson Charitable foundation 's Annual NMO Roundtable Conference 2016 from February29-March 1,2016
25. Pandit L. Demyelinating disorders in India- an over view- Invited lecture at national meeting of Association of Physicians of India (APICON), Hyderabad, January 2016.
26. Pandit L. Role of Biomarkers in the diagnosis and management of optic neuritis. Invited speaker at Synapse 2016,Shankar Nethralaya, Chennai , January2016.
27. Pandit L, Sato D, Mustafa S et al. Characterization Of Anti MOG and Anti AQP4 Antibody Associated NMOSD in South India. Paper presented at PACTRIMS, Seoul, Korea, November 2015.
28. Pandit L. Management of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders in Resource Poor Settings. Invited speaker at PACTRIMS, Seoul, Korea, November 2015.
29. Pandit L, Mustafa S, Malli C et al. Anti MOG antibody associated disease is distinct from Anti AQP4-IgG associated Neuromyelitis Optica Spectrum disorders . Paper presented at IANCON 2015,Agra.
30. Pandit L. Gene environmental interactions in Neuromyelitis optica. Invited speaker at the plenary session of Guthy Jackson Foundation International symposium, Los Angeles, USA, March 2015
31. Pandit L Challenges in the diagnosis and management of neuromyelitis optica spectrum disorders. Invited speaker at Karnataka association of neurology annual meeting, February 2015, Mangalore.
32. Pandit L , Malli C, D'Cunha A et al .HLA class II alleles and environmental associations with neuromyelitis optica in Indian population.ECTRIMS 2014 in Boston, Massachusetts, USA.
33. Pandit L: Invited speaker at panel discussion on treatment choices for Multiple Sclerosis in India. Annual conference of Indian Academy of Neurology, Chandigarh, November 2014.
34. Pandit L. Delivered keynote address on "The end points in MS disease evaluation: Clinical disability vs. relapse rate vs. Imaging" at NEUCON-Controversies in Neurology, Hyderabad 2014.
35. Pandit L. Multiple sclerosis therapeutics- Invited speaker at Dr Balaparameshwara symposium on therapeutic advances in Neuroimmunology, at Andrapradesh Neurological Society Conference, Tirupathi, June, 2014.
36. Pandit L, Malli C, D'Cunha A et al. Selective association of HLA -DRB1 alleles with Multiple Sclerosis susceptibility in Indian population. Paper presented at ECTRIMS, Copenhagen (October 2013).
37. Pandit L. Genetics of multiple sclerosis in Indians. Invited speaker at the plenary session of PACTRIMS, Kyoto, Japan (November 2013).
38. Pandit L. Neuromyelitis spectrum disorders in India. Invited speaker at the roundtable conference of the Guthy Jackson foundation, Los Angeles, California, USA (November 2013).
39. Pandit L. Neuromyelitis spectrum disorders. Invited speaker at Tropicon 2013, Tropical neurology Subsection of Indian Academy of Neurology, Guwahati, Assam (February 2013).
40. Pandit L. Treatment options In Multiple Sclerosis. Invited speaker at the Continuing medical association program, Annual meeting of Neurological society of India, New Delhi(December 2012)
41. Pandit L, Malli C, Shetty R et al. Environmental factors associated with Multiple Sclerosis. Invited talk at annual meeting of association of Sri Lankan neurologist, Colombo, SriLanka (November 2012).
42. Thompson AJ, Browne P, Taylor B, Battaglia M, Pandit L, Tremlett H, Uitdehaag B, Holloway E. MSIF Atlas of MS Database update: Multiple sclerosis resources in the world 2013. Paper presented at ECTRIMS, Lyon, France (October 2012).
43. Pandit L, Kundapur R. Mangalore model of epidemiological survey-a method for establishing minimal prevalence for demyelinating disorders in resource poor countries. Paper presented at PACTRIMS2012, Beijing, China (September 2012).
44. Pandit L, Shetty R, Singhal B et al. Environ mental factors associated with Multiple scleropsis in India. Are they different from the west?Paper presented at annual conference of Indian Academy of Neurology (September 2012, Ahmadebad).
45. Pandit L. Treatment practices for Multiple sclerosis in India. Invited speaker at Asia pacific expert committee (APEC) meeting, Hongkong, July 2012.
46. . Pandit L. Differential diagnosis of white matter diseases. Invited lecture, Kannur Neuro Club, April2012, Kerala.
47. Pandit L, Singhal B, Shetty R et al. Epstein -Barr serology in central nervous system demyelinating disorders from a south Indian disease registry. Poster presented at ECTRIMS (Sept 2011).
48. Pandit L. Genetics of Multiple sclerosis in India. Invited presentation at the plenary session of PACTRIMS 2011 (Singapore, June 2011)
49. Pandit L. Oral medications for Multiple sclerosis. Invited speaker at the national meeting on controversies in neurology Neucon2011 (Mumbai, June 2011)
50. Pandit L. Insights into MS in India. Invited speaker at the annual meeting of Kerala Association of neurologists (May2011, Wyanad, Kerala).
51. Pandit L, Ban M, Stephen Sawcer et al. Genetic risk factors for Multiple Sclerosis in Indians-Do they differ from western population? PACTRIMS, 2010.

1. Pandit L. Managing Multiple sclerosis and allied disorders during COVID-19 pandemic. In P N Sylaja (eds). Reviews in Neurology, New Delhi:Wolters Kluwer(India), Indian Academy of Neurology CME Publication; 2021: 49-56
2. Lu A, Zimmermann HG, Specovius S, Motamedi S, Chien C, Bereuter C, Lana-Peixoto MA, Fontenelle MA, Ashtari F, Kafieh R, Dehghani A, Pourazizi M, Pandit L, D'Cunha A, Kim HJ, Hyun JW, Jung SK, Leocani L, Pisa M, Radaelli M, Siritho S, May EF, Tongco C, De Sèze J, Senger T, Palace J, Roca-Fernández A, Leite MI, Sharma SM, Stiebel-Kalish H, Asgari N, Soelberg KK, Martinez-Lapiscina EH, Havla J, Mao-Draayer Y, Rimler Z, Reid A, Marignier R, Cobo-Calvo A, Altintas A, Tanriverdi U, Yildirim R, Aktas O, Ringelstein M, Albrecht P, Tavares IM, Bichuetti DB, Jacob A, Huda S, Soto de Castillo I, Petzold A, Green AJ, Yeaman MR, Smith TJ, Cook L, Paul F, Brandt AU, Oertel FC; GJCF International Clinical Consortium for NMOSD. Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry. 2021 Oct 28:jnnp-2021-327412. doi: 10.1136/jnnp-2021-327412
3. Oertel FC, Specovius S, Zimmermann HG, Chien C, Motamedi S, Bereuter C, Cook L, Lana Peixoto MA, Fontanelle MA, Kim HJ, Hyun JW, Palace J, Roca-Fernandez A, Leite MI, Sharma S, Ashtari F, Kafieh R, Dehghani A, Pourazizi M, Pandit L, D'Cunha A, Aktas O, Ringelstein M, Albrecht P, May E, Tongco C, Leocani L, Pisa M, Radaelli M, Martinez-Lapiscina EH, Stiebel-Kalish H, Siritho S, de Seze J, Senger T, Havla J, Marignier R, Calvo AC, Bichuetti D, Tavares IM, Asgari N, Soelberg K, Altintas A, Yildirim R, Tanriverdi U, Jacob A, Huda S, Rimler Z, Reid A, Mao-Draayer Y, Soto de Castillo I, Petzold A, Green AJ, Yeaman MR, Smith T, Brandt AU, Paul F. Retinal Optical Coherence Tomography in Neuromyelitis Optica. Neurol Neuroimmunol Neuroinflamm. 2021;8(6):e1068. doi: 10.1212/NXI.0000000000001068
4. Pandit L. Fair and equitable treatment for multiple sclerosis in resource-poor regions: The need for off-label therapies and regional treatment guidelines. Mult Scler 2021; 27(9):1320-1322. doi: 10.1177/13524585211028806
5. Pandit L, Malli C, D'Cunha A, Sudhir A. Overcoming the challenges in the diagnosis of AQP4-IgG positive neuromyelitis optica spectrum disorders in resource poor settings using an indigenized and cost effective cell based assay. J Neuroimmunol. 2021;360:577706. doi: 10.1016/j.jneuroim.2021.577706
6. Pandit L, Malli C, D'Cunha A, Sudhir A. Role of Viral Infections in Multiple Sclerosis pathogenesis among Indian Population. Neurol India2021;69:681-5
7. Malli C, Pandit L, D'Cunha A, Sudhir A . Coexistence of autoantibodies and other autoimmune diseases with Multiple Sclerosis and related disorders - Experience from the Mangalore Demyelinating Disease Registry (MANDDIR). Ann Indian Acad Neurol 2021 DOI:10.4103/aian.AIAN_170_21
8. Soares-dos-Reis R, Li Tsz-Ching J, Kim S H, Jacob A, Whittam D, Berthelot E, Paul F, Nakashima I, Noi Tye JS, De Seze J, Jitprapaikulsan J, Tan K, Yang L, Elsone L, Isabel Leite M, Mealy M A, Levy M, Fan M, Siebert N, Asgari N, Cabre P, Siritho S, Pittock S J, Wing-Ho SC, Senger T, Yeo T, Takai Y, Pandit L, Kim H J, Palace J, The Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence, Mult Scler Relat Disord 2021, doi: https://doi.org/10.1016/j.msard.2021.103080
9. Pandit L, Mustafa S. Epidemiology and clinical features of demyelinating disorders in India.Neurology and Clinical Neuroscience 2021: https://doi.org/10.1111/ncn3.12488
10. D'Cunha A, Pandit L, Malli C, Sudhir A. Evaluating the role of HLA DRB1 alleles and oligoclonal bands in influencing clinical course of Multiple Sclerosis- A study from the Mangalore demyelinating disease registry. Ann Indian Acad Neurol 2021: DOI: 10.4103/aian.AIAN_508_20
11. Pandit L, Cox LM, Malli C, D'Cunha A, Rooney T, Lokhande H, Willocq V, Saxena S, & Chitnis T. Clostridium bolteae is elevated in neuromyelitis optica spectrum disorder in India and shares sequence similarity with AQP4. Neurol Neuroimmunol Neuroinflamm. 2020; 8(1):e907. doi:10.1212/NXI.0000000000000907
12. Specovius S, Zimmermann HG, Oertel FC Chien C, Bereuter C, Cook L J, Lana Peixoto M A, Fontenelle M A, Kim H J, Hyun J W, Jung S K, Palace J, Fernandez A R, Diaz A R, Leite M I, Sharma S M, Ashtari F, Kafieh R, Dehghani A, Pourazizi M, Pandit L, D'cunha A et al Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO) . BMJ Open 2020; 10:e035397. doi: 10.1136/bmjopen-2019-035397
13. Whittam D H, Karthikeayan V, Gibbons E, Kneen R, Chandratre S, Ciccarelli O,   Hacohen Y, Pandit L et al. Treatment of MOG antibody associated disorders: results of an international survey. J neurol2020; doi: 10.1007/s00415-020-10026-y
14. Tenembaum S, Yeh EA and the Guthy-Jackson Foundation International Clinical Consortium (GJCF-ICC). Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis. Front. Pediatr 2020; 8: https://doi.org/10.3389/fped.2020.00339
15. Hor J Y, Asgari N, Nakashima I, Broadley S A, Leite M I, Kissani N, Jacob A, Marignier R, Weinshenker B G, Paul F, Pittock S J, Palace J, Wingerchuk DM, Behne JM, Yeaman M R and Fujihara K on behalf of the Guthy-Jackson Charitable Foundation International Clinical Consortium for NMOSD. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front. Neurol 2020: https://doi.org/10.3389/fneur.2020.00501
16. Whittam D H, Cobo-Calvo A, Lopez-Chiriboga A S, Pardo S, Gornall M, Cicconi S, Brandt, Berek K, Berger T, Jelcic I, Gombolay G, Pandit L et al. Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients. Mult Scler Relat Disord 2020: DOI: 10.1016/j.msard.2020.102251
17. Bhatia R, Padma Srivastava M V, Khurana D, Pandit L, Mathew T, Gupta S, Netravathi M, Nair SS, Singh G, Singhal BS. Consensus Statement on Immune Modulation in Multiple Sclerosis and Related Disorders during the COVID‑19 Pandemic: Expert Group on Behalf of the Indian Academy of Neurology. Ann Ind Acad Neurol 2020;23:5-14
18. Cook L J, Rose J W, Alvey J S, Jolle A M, Kuhn R, Yeaman M R on behalf of The Guthy-Jackson Charitable Foundation International Clinical Consortium (GJCF-ICC).Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD.Neurol Neuroimmunol Neuroinflamm 2019;6 (5): e583
19. Pandit L. No evidence of disease activity (NEDA) in multiple sclerosis - Shifting the goal posts .Ann Ind Acad Neurol 2019; 22: 261-263
20. Pandit L, Mustafa S, Nakashima I et al. MOG-IgG-associated disease has a stereotypical clinical course, asymptomatic visual impairment and good treatment response Mult Scler J Exp Transl Clin. 2018;4(3) : 1-9
21. Pandit L, Mustafa S, Uppoor R et al. Reversible paraspinal muscle hyperintensity in anti-mog antibody-associated transverse myelitis. Neurol Neuroimmunol Neuroinflamm 2018; 5:e412
22. Pandit L, Nakashima I, Mustafa S et al. Anti Myelin Oligodendrocyte Glycoprotein associated Immunoglobulin G (AntiMOG‑IgG)‑associated Neuromyelitis Optica Spectrum Disorder with Persistent Disease Activity and Residual Cognitive Impairment. Ann Ind Acad Neurol 2017; 20:411-3.
23. Pandit L, Mustafa S. Spontaneous remission lasting more than a decade in untreated aqp4antibody-positive NMOSD. Neurol Neuroimmunol Neuroinflamm 2017;4:e351
24. D'Cunha A, Pandit L, Malli C. Genetic variations in the Dravidian population of South West coast of India: Implications in designing case-control studies. Indian J Med Res 2017;145: 753-757
25. Steinman L, Bar-Or A, Behne JM, et al. Restoring immune tolerance in neuromyelitis optica: Part I. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e276
26. Bar-Or A, Steinman L, Behne JM, et al. Restoring immune tolerance in neuromyelitis optica: Part II. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e277
27. Pandit L, Sato D, Mustafa S et al. Serological markers associated with   NMO spectrum disorders in south India. Ann Indian Acad Neurol 2016;19:505‑509
28. D'Cunha A, Pandit L, Malli C. CD6 gene polymorphism rs17824933 is associated with multiple sclerosis in Indian population. Ann Ind Acad Neurol 2016;19:491‑494
29. Pandit L, Sato D, Mustafa S et al. Relapsing optic neuritis and isolated transverse myelitis are the predominant clinical phenotypes for patients with antibodies to myelin oligodendrocyte glycoprotein in India. Mult Scler J Exp Trans Clinic 2016; 2:1-5
30. Pandit L, Maria B, Beecham AH et al. European multiple sclerosis risk variants in the south Asian population. Mult Scler 2016; 22(12):1536-1540.
31. Pandit L, Malli C, Singhal B et al. HLA association in South Asian Multiple Sclerosis. Mult Scler 2016;22(1):19-24
32. Juryńczyk M, Weinshenker B, Pandit L et al. Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. J Neurol. 2016; 263(1):140-9
33. Pandit L. Neuromyelitis optica spectrum disorders-an update. Ann Ind Acad Neurol 2015; 18:S11:15.
34. Weinshenker BG, Barron G, Behne JM, Guthy-Jackson Charitable Foundation International Clinical Consortium. Challenges and opportunities in designing clinical trials for neuromyelitis optica. Neurology2015 28;84(17):1805-15
35. Melamed E, Levy M, Pandit L et al. Update on Biomarkers in Neuromyelitis Optica. Neurol Neuroinflam 2015 23; 2(4):e134
36. Kim HJ, Paul F, Lana-Peixoto MA, Guthy-Jackson Charitable Foundation NMO International Clinical Consortium & Biorepository. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 2015 Mar 17; 84(11):1165-73
37. Kremer S, Renard F, Achard S , Guthy-Jackson Charitable Foundation NMO International Clinical Consortium. Use of advanced MRI techniques in Neuromyelitis optica spectrum disorders. JAMA Neurol. 2015;72(7):815-822
38. Pandit L, Malli C, D'Cunha A et al. HLA association in Neuromyelitis Optica in Indian population . Mult Scler 2015; 21(9):1217-8
39. Bennett JL, Seze J de, Peixoto ML, Guthy-Jackson Charitable Foundation NMO International Clinical Consortium & Biorepository et al.Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. Mult Scler 2015;21(6):678-88
40. Malli C, Pandit L, D'Cunha A et al. Environmental factors related to Multiple sclerosis in Indian population. 2015 PLoS ONE 10(4): e0124064
41. Pandit L, Asgari N, Apiwattanakul M et al. Demographic and Clinical features of Neuromyelitis optica- A review. Mult scler 2015; 21(7):845-53
42. Pandit L, Mustafa S. Mycophenolate in the treatment of Multiple Sclerosis- A preliminary report. Neurol India 2014; 62: 646- 648
43. Mustafa S, Pandit L. Approach to diagnosis and management of optic neuropathy. Neurol India 2014; 62: 599- 605
44. Pandit L, Kundapur R. Prevalence and patterns of demyelinating central nervous system disorders in urban Mangalore, South India in India. Mult Scler 2014; 20:1651-3
45. Pandit L,Mustafa S. Optimizing the management of Neuromyelitis Optica and Spectrum disorders in resource poor settings: Experience from the Mangalore demyelinating disease registry. Ann Ind Academy Neurol.2013; 16: 572- 576
46. Pandit L, Ramagopalan SV, Malli C, D'Cunha A, Kunder R, Shetty R,  Association of vitamin D and multiple sclerosis in India. Mult Scler 2013; 19:1592- 1596
47. Pandit L, Malli C, D'Cunha A et al. Association of Epstein-Barr virus infection with multiple sclerosis in India. J Neurol Sci 2013;325: 86-89
48. Pandit L, Shetty R, Misri Z et al. Optic neuritis: Experiences from a south Indian demyelinating disease registry. Neurol India 2012; 60: 470-475
49. Pandit L. Insights into the changing perspectives of multiple sclerosis in India. Autoimmune diseases.2011, Doi:10.4061/2011/937586
50. Pandit L, Murthy JMK. Treatment of Multiple Sclerosis. Ann Ind Acad Neurol. 2011;14: 65-69
51. Pandit L, Ban M, Sawcer N et al. Evaluation of the established non-MHC Multiple Sclerosis loci in an Indian Population. Mult Scler 2011; 17:139-143
52. Pandit L, Ban M, Sawcer N et al. Genetic risk factors for multiple sclerosis in Indians: Do they differ from western populations? Mult Scler 2010; 16: S1268- S1273
53. Pandit L, Shetty R, Mustafa S et al. Optic spinal MS in India is distinct from NMO - Clinical and HLA class 11 association studies. Mult Scler 2010; 16: S263-S280
54. Pandit L, Shetty R, Bhat IG et al. Seronegative neuromyelitis spectrum disorders in India. Mult Scler 2009; 5: S15-S269
55. Pandit L. Mitoxantrone in MS-Invited commentary. Neurol India 2009; 57:424-425
56. Pandit L. Transverse myelitis spectrum disorders. Neurol India 2009; 57:126-132
57. Pandit L.. Differential diagnosis of white matter diseases in the tropics. Ann Indian Acad Neurol 2009;12:12-21.
58. Pandit L. Neuromyelitis optica antibody (NMO-IgG) status in Indian patients with multiple sclerosis and allied demyelinating disorders. Neurol Asia 2008; 13 : 175- 178
59. Pandit L NMO-IgG in Indian patients with Multiple sclerosis & allied idiopathic inflammatory demyelinating disorders of the central nervous system. Mult Scler 2009; 15:131-136
60. Pandit L, Shetty R, Bhat IG et al .Anti - Aquaporin 4 antibody seropositivity in Multiple Sclerosis and allied demyelinating disorders in Indian patients. Ann Ind Acad Neurol 2008; 11(S2)138-139
61. Pandit L Multiple sclerosis and allied demyelinating disorders in India. Advances in clinical neurosciences and rehabilitation (ACNR) 2008; 8:30-31
62. Pandit L, Shetty R, Bhat IG et al. Spectrum of Multiple Sclerosis and related demyelinating disorders in India in the background of revised diagnostic criteria Ann Ind Acad Neurol 2007;10: (S2) 44-45
63. Pandit L, Pai M, Shankar SK et al. Multifocal tumour like presentation of white matter- a case report. Neurol India. 1998; 46 : S96
64. Pandit L, Beveridge C, Coulthard C et al. Predictors of disability in Multiple sclerosis. Neurol India.1998; 46: S67- 68
65. Pandit L, Dickenson A, Bates D. Cytokine and Adhesion molecule profile in Multiple Sclerosis patients following Intravenous High dose Methyl Prednisolone. Neurol India. 1997; 45:S66-67
66. Pandit L, Coulthard C, Bates D. Clinical and Radiological correlation of disability in Multiple Sclerosis. J Neurol Neurosurg Psychiatry1997; 63:262- 272
67. Pandit L, Rao SN. Multiphasic Disseminated Encephalomyelitis. Neurology India 1998; 46:74-75.
68. Pandit L, Rao S N. Recurrent Myelitis. Journal of Neurology Neurosurgery and Psychiatry 1996; 60: 336-338
69. Pandit L, Subramania R, Rao S N. Multiple Sclerosis in Costal Karnataka. Neurol India 1993;41: 143-146. Chapters in Books
70. Pandit L. Demyelinating disorders of the CNS. In: Kamath S (ed). API textbook of Medicine.11th ed. CBS publishers; 2019
71. Pandit L. Neuromyelitis Optica Spectrum Disorders. In: IAN Textbook of Neurology: Jaypee Brothers; 2018
72. Pandit L. Demyelinating disorders in India-An update In: Wander GS (ed) Medicine Update Mumbai: Jaypee Brothers; 2016
73. Singhal BS, Pandit L. Multiple sclerosis in the tropics. In: Chopra & Sawhney (eds). Neurology in the tropics.11nd ed. Elsevier Asia.2015.
74. Pandit L, Jacob A. Neuromyelitis and spectrum disorders. In: Chopra & Sawhney (eds). Neurology in the tropics.11nd ed. Elsevier Asia, 2015
75. Pandit L, Mustafa S. Optic neuropathy in the India; a brief overview. In: Singh G, Das SK (eds) Reviews in Neurology, New Delhi: Elsevier India;  2014: 24-28
76. Pandit L. Multiple sclerosis: Treatment options. In: Singh VP, Nair MD (eds). Progress in Clin Neuroscience, Vol. 27. New Delhi: Byword Books; 2013: 62-70
77. Pandit L. Immunology & Immunogenetics of Multiple sclerosis. In: Taly AB, Singh, G.(eds) Reviews in Neurology. CME program of Indian Academy of Neurology; 2009
78. Agrawal A, Dhaval P, Pandit L. Stroke in Pregnancy in Candolotti JT and Burnside JE ( eds).women and stroke research, Nova Publishers,2008
79. Agrawal A, Dhaval P, Pandit L. Tumor and stroke in Candolotti JT and Burnside JE ( eds).women and stroke research, Nova Publishers,2008
80. Agrawal A, Dhaval P, Pandit L. Cerebral venous thrombosis in Candolotti JT and Burnside JE ( eds).women and stroke research, Nova Publishers,2008
81. Agrawal A, Dhaval P, Pandit L. Stroke in developing countries, in Candolotti JT and Burnside JE ( eds).women and stroke research, Nova Publishers,2008
82. Pandit L. Impact of Molecular Genetics on the diagnosis and management of neurological disorders. In: Radhakrishnan K (ed) Reviews in Indian Neurology 2005, Indian Academy of Neurology CME Publication; 2005: 33-46
83. Pandit L. Demyelinating disorders of the Central Nervous System with relevance to India. In: Radhakrishnan K (ed) Reviews in Indian Neurology 2004, Indian Academy of Neurology CME Publication;2004: 65-79
84. Pandit L. The role of PCR in the diagnosis of CNS infections: a developing country perspective. In: Radhakrishnan K (ed) Reviews in Indian Neurology 2003, Indian Academy of Neurology CME Publication;2003: 50-71
85. Pandit L. Immunogenetics in Neurological disorders -An overview. Progress in Clinical Neurosciences 1995; 10: 63-81. Other publications
86. Pandit L. Coexistence of autoimmune diseases and autoantibodies in patients with myasthenia gravis. Neurol India 2016;64:7
87. Raghotham A, Pandit L. Large unruptured proximal (A1) anterior cerebral artery aneurysm with aplasia of the contralateral A1.Neurol India 2014; 62:80- 82.
88. Pandit L, Chickabasaviah Y, Ragotham A et al. Neoplastic Parkinsonism- An illustrative case report . Ann Ind Acad Neurol 2013; 16:441- 443
89. Pandit L, Yasha M, Anandan N et al. Lymphomatosis cerebri -a rare cause of leucoencephalopathy . J Neurol Sci 2010: 293:122-124
90. Pandit L, Narayanappa G, Bhat IG et al. Autosomal recessive tubular aggregate myopathy in an Indian family. Eur J Paed Neurol. 2009; 13:373-375
91. Pandit L, Agrawal A, Mudgal S et al. Tuberculous spinal meningitis - a treatable cause of myeloradiculopathy. Infect Dis Clin Pract.2009; 17:281-282
92. Agrawal A, Joharapurkar SR, Pandit L et al. Infect Disease Clin Pract.2008; 16: 345-348
93. Agrawal A, Jake T, Pandit L et al. Management of subdural hematoma. Infect Disease Clin Pract.2007; 15:149-153
94. Agrawal A, Pandit L, Bhandary S et al: Diagnostic and therapeutic aspects.. Singapore Med J 2007; 48: e181-185
95. Agrawal A, Shetty MS, Pandit L et al. Post-traumatic syringomyelia. Ind J Orthop 2007;41:398-400
96. Pandit L, Gayathri N, Shetty L et al. Adult onset Leigh syndrome - a case report. Ann Indian Acad Neurol 2007;10:55-57
97. Agrawal A, Pandit L, NayakV, et al. Pre-Chiasmatic nerve injury following frontal contusion. Eur J Gen Med 2007;4:45-47
98. Agrawal A, Timothy J, Pandit L et al. Neurogenic pulmonary odema. Eur J Gen Med. 2007;4 :25-32
99. Pandit L, Agarwal A. Neuromuscular dysfunction in critical illness. Clinical Neurol Neurosurgery. 2006; 108: 621-627
100. Pandit L, Agrawal A. Cryptococcal meningitis in a non HIV patient. Eur J Gen Med 2006;3:80-82
101. Agrawal A, Pandit L. Hyperdense middle cerebral artery sign. Eur J Gen Med 2006; 3:45-47
102. Agarwal A, Timothy J, Pandit L et al. Post traumatic Epilepsy-An over view. Clin Neurol Neurosurg. 2006; 108: 433-9.
103. Pandit L, Kumar S, Karunasagar I et al. Diagnosis of Partially Treated Culture Negative Bacterial Meningitis Using 16S rRNA Universal Primers and Restriction Endonuclease Digestion. J Med Microbiol.2005;54:1-4.
104. Karunasagar A, Pandit L, Kumar S et al I. Use of methylation sensitive PCR in the evaluation of fragile X syndrome . Ind J Med Res 2005; 122: 429-433
105. Agarwal A, Pandit L, Bhandary S. et al. Extensive subdural empyema, paranasal sinusitis and orbital cellulitis complicating nasal septum surgery in a child: a case report and review of literature. Paed on call http://www.pediatriconcall.com/ fordoctor/ casereports /NasalSeptumSurgery.asp
106. Agarwal A, Pandit L, Dalal M et al. Neurological manifestations of Hansen's disease and their management. Clin Neurol Neurosurg 2005; 107: 445-454
107. Agrawal A, Pandit L. Aetio-pathology, Diagnosis and Management of chronic neck pain. Orthopedics 2005; 7: 235-241
108. Thomas SV, Sarma PS, Pandit L et al. Epilepsy care in six Indian cities: a multicenter study on management and service. J Neurol Sci 2001; 188: 73-72
109. Thomas SV, Sarma PS, Pandit L et al.Economic burden of epilepsy in India. Epilepsia 2001; 42:1052-60
110. Pandit L, Shanker SK, Pandit A. Acute Thyrotoxic Neuropathy -Basedows Paraplegia revisited. J Neurol Sci 1998; 155: 211-214.
111. Pandit L, Unni N, Rao S N. Secondary Hypokalaemic Periodic Paralysis. J Assoc Physician India, 45: 421-423, 1996.
112. Prabhu GGL, Rao MS, Pandit L et al. Minor variant of alstrom syndrome : report of a case presenting with a perinephric abscess. Ind J Urol 1996; 12: 45-48.
113. Pandit L, Rao S N. Thymomatous Myasthenia Gravis. J Assoc Physician India 1995; 43: 543- 545.
114. Pandit L, Pandit A, Aggarwal A et al. Mechanism of voiding dysfunction in the immediate Post- Stroke period. Neurol India 1994; 40: 3-5.
115. Pandit L, Rao S N. Computerised Tomography in Tolosa - Hunt Syndrome. Ind J Ophthalmol 1994; 42: 207-209.
116. Pandit L, Kapadia R, Kini P et al. Metachromatic Leukodystrophy presenting with extrapyramidal disturbances. Indian Paediatrics 1994; 31: 690-694.
117. Pandit L, Subramania R, Rao S N. Global aphasia without hemiparesis, clinicoradiological study of three cases. Neurol India 1992; 40: 170-181 Publications related to Drug Trials:
118. Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020; 383(6):546-557.
119. Fox RJ, Chan A, Gold R et al. Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerations. Neurol Clin Pract 2016;6(3):220-229 .
120. Conry JA, Ng YT, Kernitsky L, et al. Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years. Epilepsia 2014;55(4):558-567.
121. Calabresi PA, Kieseier BC, Pandit L et al. ADVANCE Study Investigators. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.Lancet Neurol. 2014; 13657-65.
122. Ng YT, Conry J, Pandit L et al. OV-1004 study investigators Long-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: interim results of an open-label extension study.Epilepsy Behav. 2012; 25: 687-94.
123. Gold R, Kappos L, Pandit L et al. DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098-10.
124. Abraham WT, Decaux G, Pandit L et al. HARMONY Study Group. Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney Int.2012 ;82:1215- 22
125. Ho TW, Pearlman E, Pandit L et al. Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. Rizatriptan Protocol 082 Pediatric Migraine Study Group. Cephalalgia. 2012 ;32: 750-65.
126. Ng YT, Conry JA, Pandit L et al. OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology. 2011;77:1473-81. Conference proceeding in Pubmed indexed journals
127. Pandit L, Cox L, Lokhande H, Rooney T, Malli C, D'Cunha A, Willocq V, Saxena S, Chitnis T. Lachnoclostridium species are elevated in aquaporin-4 (AQP4+) neuromyelitis optica patients in India and exhibit sequence similarity with AQP4. Mult Scler J 2019; 25: (S2) 224- 225.
128. Soares dos Reis R, Li Tsz-Ching J, Kim H, D'Cunha A, Jacob A, Berthelot E, Pandit L et al. Influence of migration on the prognosis of neuromyelitis optica spectrum disorder in non- Caucasian patients. Mult Scler J 2019; 25: (S2) 138-139
129. Specovius S, Zimmermann H.G, Chien C, Pandit L et al. The CROCTINO project: an international retrospective multi-center study of retinal optical coherence tomography in 501 patients with neuromyelitis optica spectrum disorders. Mult Scler J 2018;24: (s2) 530-737
130. Pandit L. Autoimmune Encephalitis. Mult Scler J 2018; 368-423.
131. Whittam D, Cobo-Calvo A, Pandit L et al. Treatment of MOG-IgG-associated demyelination with Rituximab: a multinational study of 98 patients S13.003. Neurology 2018: 90 (15 Supplement).
132. Huda S, AlOrainy A, Pandit L et al. MRI abnormalities in MOG antibody disease. J Neurol Neurosurg Psychiatry2018: 89;A44-A45.
133. Pandit L, Sato D, Siritho S et al. Characterization of seronegative neuromyelitis optica in 2016. Mult Scler J 2016; 22: (S3) 92.
134. Pandit L. Differentiating Multiple sclerosis from NMOSD in the clinic. Ann Ind Acad Neurol.2016. 19(S)1-132.
135. Pandit L, Sato D, Mustafa S et al. Characterization Of Anti MOG and Anti AQP4 Antibody Associated NMOS in A South Indian Cohort. Mult Scler J 2015; O-2: 21.
136. Pandit L. Management of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders in Resource poor settings. Mult Scler J 2015; L-16: 18.
137. Pandit L, Mustafa S, Malli C et al. Anti MOG antibody associated disease is distinct from Anti AQP4-IgG associated Neuromyelitis Optica Spectrum disorders. Ann Ind Acad Neurol 2015; 18: S33-34.
138. Sato DK, Kaneko K, Pandit L et al. Clinical phenotypes of pediatric and adult patients with anti-MOG antibodies. Mult Scler 2015; 21: (S11) 76-653.
139. Pandit L, Malli C, D'Cunha A et al .HLA class II alleles and environmental associations with neuromyelitis optica in Indian population. Mult Scler 2014; 20: suppl 285-496.
140. Pandit L. Genetics of multiple sclerosis in Indians. Mult Scler 2014;20: (7) 902
141. Pandit L, Malli C, D'Cunha A et al. Selective association of HLA -DRB1 alleles with Multiple Sclerosis susceptibility in Indian population. Mult Scler 2013; 19: (S1) 74-558.
142. Pandit L, Kundapur R. Mangalore model of epidemiological survey-a method for establishing minimal prevalence for demyelinating disorders in resource poor countries. Mult Scler J 2013; 19: 644- 702.
143. Pandit L. Genetics of Multiple sclerosis in India . Mult Scler J 2012 18: S515-548
144. Pandit L, Singhal B, Shetty R et al. Epstein -Barr serology in central nervous system demyelinating disorders from a south Indian disease registry. Mult Scler J 2011; 17: S53-S276.
145. Pandit L, Ban M, Sawcer N et al. Genetic risk factors for multiple sclerosis in Indians: Do they differ from western populations? Mult Scler 2010; 16: S1268- S1273.
146. Pandit L,Ban M,Sawcer S,Singhal B,Nair S,Radhakrishnan K,Shetty R,Misri Z,Hegde S.Bhat I.Multiple sclerosis in India:Genetic susceptibility is not different from the west.Ann Ind Acad Neurol 2010; 13:5 SUPPL. 1 (S49)

Research Grants Title	Funding Agency	Amount
Identifying and characterizing Aquaporin -4 specific T cells in Neuromyelitis optica spectrum disorders	Nitte (Deemed to be University) 2020-2021	Rs 1,99,948
Development of a sensitive cell based assay for the detection of a diagnostic biomarker (Myelin oligodendrocyte glycoprotein antibody) in Neuromyelitis optica spectrum disorders	ICMR (2020-2023)	Rs 30,72,528
Indian Multiple Sclerosis and Allied Demyelinating Disorders Registry and Research Network	ICMR (2020-2025)	Rs 32,29,000
Use of Wistar rat brain sections in Immunohistochemistry studies for characterization of seronegative Neuromyelitis optica spectrum disorders-A pilot study	Nitte (Deemed to be University) 2019-2020	Rs 1,40,000
Evaluation of AQP4-IgG administration with human complement for developing Neuromyelitis optica spectrum disorder (NMOSD) rodent mouse model - A pilot study	Nitte (Deemed to be University) 2019-2020	Rs 1,25,000
"Development of a cost effective cell based assay for the diagnosis of Neuromyelitis optica spectrum disorders in India"	DBT-BIRAC (2019-2021)	Rs 40,93,000
Neuromyelitis optica Biomarker assay development - Phase1 (Culture & Maintenance of Human Embryonic Kidney cell lines for development of cell based biomarker assay for sensitive diagnosis of Neuromyelitis optica spectrum disorders.)	Nitte University (2015-2016)	Rs1,20,000
Understanding the role of herpes viruses and human endogenous retrovirus in MS pathogenesis	Dept of Biotechnology (2014-2017)	Rs 65,00,000
Environmental & genetic risk factors for MS in Indian population	Dept of Science & Technology, Govt of India (2011-2014)	Rs 58,01,282
Study of European risk variants in MS in Indian population	MS society of Great Britain (2013-2014)	Rs 15,00,000
Association of H pylori with NMO and NMO spectrum disorders among Indian population	Nitte University (2014-2015)	Rs1,33,900
Association of HLA Class I (A&C) Alleles in Multiple Sclerosis among Indian population- a pilot study	Nitte University (2013-2014)	Rs 2,05,375
Study of patterns and prevalence of demyelinating disorders in urban Mangalore	Indian council of medical research (2010-2013)	Rs 35,80,000
Evaluation of Anti Aquaporin Antibody in Indan Demyelinating disorders (collaboration with Professor Weinshenker, Mayoclinic, Minnesotta, USA)	Intramural funding (2007-2008)	Rs 1,00,000
A longitudinal study to determine the clinical and radiological predictors for ADEM and MS and to evaluate underlying genetic susceptibility.	Indian council of Medical research (2007-2010)	Rs 12,50,000
Molecular genetics & genetic epi demiology of some common triplet repeat disorders in Coastal Karnataka	Dept.of Science & Technology, (DST,Govt of India) (2006-2009)	Rs 19,00,000
Molecular Characterization of Campylo- bacter jejuni infection associated with Guillane -Barre syndrome	Life Science research Board (DRDO,Govt of India ) (2005-2007)	Rs10,80,000
Evaluation of Fragile X syndrome as cause of mental retardation	Indian council of medical of research (ICMR) & Nitte Educational Trust (2002-2003)	Rs 25, 000
Use of universal primers in the diagnosis Of culture negative meningitis Use of semi nested PCR in diagnosis of Culture negative meningitis	Rhodes Scholar Mridula Shastri memorial post-doctoral scholarship (2001-2002)	Rs 1,00,000

Teaching of medical undergraduates, post graduates in Internal medicine ,Psychiatry and Pediatrics and providing guidance for PhD students in my lab